Drug Profile


Alternative Names: Canagliflozin-hydrate; Canaglu; Invokana; JNJ-28431754; Sulisent; TA-7284

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tanabe Seiyaku
  • Developer Daiichi Sankyo Company; Janssen; Johnson & Johnson; Mitsubishi Tanabe Pharma Corporation
  • Class Antihyperglycaemics; Glucosides; Small molecules; Thiophenes
  • Mechanism of Action Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Phase III Diabetic nephropathies
  • Phase II Obesity; Type 1 diabetes mellitus

Most Recent Events

  • 25 Aug 2017 Phase-III clinical trials in Type-2 diabetes mellitus (In children, In adolescents) in USA (PO) (NCT03170518)
  • 21 Aug 2017 Canagliflozin licensed to Mundipharma Medical Company in Austria, Belgium, Bulgaria, the Czech Republic, Denmark, Ireland, Luxembourg, the Netherlands, Poland, Slovakia, Sweden and Switzerland
  • 30 Jun 2017 Mitsubishi Tanabe completes a clinical trial in Type 2 diabetes mellitus in Japan (UMIN000018814)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top